23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

9-2015

Volume

51

Issue

3

First Page

721

Last Page

721

Published In/Presented At

https://doi.org/10.1016/S0959-8049(16)31943-8

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article